PMC:7035340 / 9377-10099 JSONTXT

{"project":"LitCovid-PubTator","denotations":[{"id":"298","span":{"begin":107,"end":116},"obj":"Species"},{"id":"299","span":{"begin":180,"end":188},"obj":"Species"},{"id":"300","span":{"begin":334,"end":342},"obj":"Species"},{"id":"301","span":{"begin":348,"end":357},"obj":"Species"},{"id":"302","span":{"begin":692,"end":701},"obj":"Species"},{"id":"303","span":{"begin":176,"end":179},"obj":"Disease"},{"id":"304","span":{"begin":319,"end":333},"obj":"Disease"},{"id":"305","span":{"begin":675,"end":686},"obj":"Disease"}],"attributes":[{"id":"A298","pred":"tao:has_database_id","subj":"298","obj":"Tax:2697049"},{"id":"A299","pred":"tao:has_database_id","subj":"299","obj":"Tax:9606"},{"id":"A300","pred":"tao:has_database_id","subj":"300","obj":"Tax:9606"},{"id":"A301","pred":"tao:has_database_id","subj":"301","obj":"Tax:2697049"},{"id":"A302","pred":"tao:has_database_id","subj":"302","obj":"Tax:2697049"},{"id":"A303","pred":"tao:has_database_id","subj":"303","obj":"MESH:C000657245"},{"id":"A304","pred":"tao:has_database_id","subj":"304","obj":"MESH:D016638"},{"id":"A305","pred":"tao:has_database_id","subj":"305","obj":"MESH:D055370"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"In conclusion, Chinese government has taken effective measures to prevent a possible national or worldwide 2019-nCoV pandemic. Offering the most reasonable treatment to severe NCP patients could be another challenge we will face. We endorse the potential benefits from low-dose corticosteroids treatment in a subset of critically ill patients with 2019-nCoV based on existing studies and clinical experience, despite there is no significant improvement in overall survival. Certainly, our ongoing well-designed prospective cohort study with sufficient samples may provide systematic answers to this clinical dilemma—“to use or not to use corticosteroids for the treatment of lung injury with 2019-nCoV”—in the near future."}

{"project":"LitCovid-PD-FMA-UBERON","denotations":[{"id":"T12","span":{"begin":224,"end":228},"obj":"Body_part"},{"id":"T13","span":{"begin":675,"end":679},"obj":"Body_part"}],"attributes":[{"id":"A12","pred":"fma_id","subj":"T12","obj":"http://purl.org/sig/ont/fma/fma24728"},{"id":"A13","pred":"fma_id","subj":"T13","obj":"http://purl.org/sig/ont/fma/fma7195"}],"text":"In conclusion, Chinese government has taken effective measures to prevent a possible national or worldwide 2019-nCoV pandemic. Offering the most reasonable treatment to severe NCP patients could be another challenge we will face. We endorse the potential benefits from low-dose corticosteroids treatment in a subset of critically ill patients with 2019-nCoV based on existing studies and clinical experience, despite there is no significant improvement in overall survival. Certainly, our ongoing well-designed prospective cohort study with sufficient samples may provide systematic answers to this clinical dilemma—“to use or not to use corticosteroids for the treatment of lung injury with 2019-nCoV”—in the near future."}

{"project":"LitCovid-PD-UBERON","denotations":[{"id":"T7","span":{"begin":224,"end":228},"obj":"Body_part"},{"id":"T8","span":{"begin":675,"end":679},"obj":"Body_part"}],"attributes":[{"id":"A7","pred":"uberon_id","subj":"T7","obj":"http://purl.obolibrary.org/obo/UBERON_0001456"},{"id":"A8","pred":"uberon_id","subj":"T8","obj":"http://purl.obolibrary.org/obo/UBERON_0002048"}],"text":"In conclusion, Chinese government has taken effective measures to prevent a possible national or worldwide 2019-nCoV pandemic. Offering the most reasonable treatment to severe NCP patients could be another challenge we will face. We endorse the potential benefits from low-dose corticosteroids treatment in a subset of critically ill patients with 2019-nCoV based on existing studies and clinical experience, despite there is no significant improvement in overall survival. Certainly, our ongoing well-designed prospective cohort study with sufficient samples may provide systematic answers to this clinical dilemma—“to use or not to use corticosteroids for the treatment of lung injury with 2019-nCoV”—in the near future."}

{"project":"LitCovid-PD-MONDO","denotations":[{"id":"T46","span":{"begin":680,"end":686},"obj":"Disease"}],"attributes":[{"id":"A46","pred":"mondo_id","subj":"T46","obj":"http://purl.obolibrary.org/obo/MONDO_0021178"}],"text":"In conclusion, Chinese government has taken effective measures to prevent a possible national or worldwide 2019-nCoV pandemic. Offering the most reasonable treatment to severe NCP patients could be another challenge we will face. We endorse the potential benefits from low-dose corticosteroids treatment in a subset of critically ill patients with 2019-nCoV based on existing studies and clinical experience, despite there is no significant improvement in overall survival. Certainly, our ongoing well-designed prospective cohort study with sufficient samples may provide systematic answers to this clinical dilemma—“to use or not to use corticosteroids for the treatment of lung injury with 2019-nCoV”—in the near future."}

{"project":"LitCovid-PD-CLO","denotations":[{"id":"T33","span":{"begin":34,"end":37},"obj":"http://purl.obolibrary.org/obo/CLO_0051582"},{"id":"T34","span":{"begin":74,"end":75},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T35","span":{"begin":224,"end":228},"obj":"http://purl.obolibrary.org/obo/UBERON_0001456"},{"id":"T36","span":{"begin":307,"end":308},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T37","span":{"begin":675,"end":679},"obj":"http://purl.obolibrary.org/obo/UBERON_0002048"},{"id":"T38","span":{"begin":675,"end":679},"obj":"http://www.ebi.ac.uk/efo/EFO_0000934"}],"text":"In conclusion, Chinese government has taken effective measures to prevent a possible national or worldwide 2019-nCoV pandemic. Offering the most reasonable treatment to severe NCP patients could be another challenge we will face. We endorse the potential benefits from low-dose corticosteroids treatment in a subset of critically ill patients with 2019-nCoV based on existing studies and clinical experience, despite there is no significant improvement in overall survival. Certainly, our ongoing well-designed prospective cohort study with sufficient samples may provide systematic answers to this clinical dilemma—“to use or not to use corticosteroids for the treatment of lung injury with 2019-nCoV”—in the near future."}

{"project":"LitCovid-PD-CHEBI","denotations":[{"id":"T58","span":{"begin":278,"end":293},"obj":"Chemical"},{"id":"T59","span":{"begin":638,"end":653},"obj":"Chemical"}],"attributes":[{"id":"A58","pred":"chebi_id","subj":"T58","obj":"http://purl.obolibrary.org/obo/CHEBI_50858"},{"id":"A59","pred":"chebi_id","subj":"T59","obj":"http://purl.obolibrary.org/obo/CHEBI_50858"}],"text":"In conclusion, Chinese government has taken effective measures to prevent a possible national or worldwide 2019-nCoV pandemic. Offering the most reasonable treatment to severe NCP patients could be another challenge we will face. We endorse the potential benefits from low-dose corticosteroids treatment in a subset of critically ill patients with 2019-nCoV based on existing studies and clinical experience, despite there is no significant improvement in overall survival. Certainly, our ongoing well-designed prospective cohort study with sufficient samples may provide systematic answers to this clinical dilemma—“to use or not to use corticosteroids for the treatment of lung injury with 2019-nCoV”—in the near future."}

{"project":"LitCovid-sentences","denotations":[{"id":"T47","span":{"begin":0,"end":126},"obj":"Sentence"},{"id":"T48","span":{"begin":127,"end":229},"obj":"Sentence"},{"id":"T49","span":{"begin":230,"end":473},"obj":"Sentence"},{"id":"T50","span":{"begin":474,"end":722},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"In conclusion, Chinese government has taken effective measures to prevent a possible national or worldwide 2019-nCoV pandemic. Offering the most reasonable treatment to severe NCP patients could be another challenge we will face. We endorse the potential benefits from low-dose corticosteroids treatment in a subset of critically ill patients with 2019-nCoV based on existing studies and clinical experience, despite there is no significant improvement in overall survival. Certainly, our ongoing well-designed prospective cohort study with sufficient samples may provide systematic answers to this clinical dilemma—“to use or not to use corticosteroids for the treatment of lung injury with 2019-nCoV”—in the near future."}